FDHT PET/CT for radio-recurrent prostate cancer

Recurrent prostate cancer occurs often and is preceded by a rise in PSA (prostate specific antigen). If the rise is more than 2 ng/mL above nadir, this is defined as a biochemical Recurrence (BCR). BCR precedes clinical evident recurrence by years. Restaging with imaging methods is necessary to determine the localisation of recurrence and the adequate treatment. Current restaging is performed with 11C-choline PET/CT or a 68Ga-PSMA PET/CT, Studies on PSMA PET/CT the past few years are very promising and current literature shows that PSMA has a higher detection rate and accuracy than choline in most clinical circumstances (primary vs recurrent and detection of metastases versus local recurrence). In our academic centre there are currently two trials running with 18 F-FDHT PET/CT. Results are promising, but more research is needed to determine exact value of the PET tracer scans. We want to assess if this PET tracer can aid in an optimal selection of patients who are eligible for salvage therapy. So no patients undergo invasive treatment, while they have advanced disease, and therefore undergo unnecessary invasive and possible toxic treatment.

to assess the detection rate and accuracy of 18 F-FDHT PET/CT and compare to current standard restaging modalities.

1 meetpunt

nvt